Background. Proton pump inhibitor and histamine-2 receptor antagonist can prevent aspirin-related ulcers/erosions but few\nstudies compare the efficacy of these two agents. Aims. We evaluated the efficacy of omeprazole and famotidine in preventing\nrecurrent ulcers/erosions in low-dose aspirin users. Methods.The 24-week clinical outcomes of the patients using low-dose aspirin\nfor cardiovascular protection with a history of ulcers/erosions and cotherapy of omeprazole or famotidine were retrospectively\nreviewed. The incidence of gastrointestinal symptoms, recurrent ulcers/erosions, erosive esophagitis, gastrointestinal bleeding, and\nthromboembolic events was analyzed. Results. A total of 104 patients (famotidine group, 49 patients; omeprazole group, 55 patients)\nwere evaluated. Famotidine group had more gastrointestinal symptoms episodes than omeprazole group (46.9% versus 23.6%,\nP = 0.01). Fifteen famotidine group patients and 5 omeprazole group patients had recurrent ulcers/erosions (30.6% versus 9.1%,\nP = 0.005). Lanza scale was significantly lower in omeprazole group than in famotidine group (1.2�±0.7 versus 1.7�±1.1, P = 0.008).\nOnly 1 famotidine group patient had ulcer bleeding. The incidences of erosive esophagitis and thromboembolic events were\ncomparable between both groups. Conclusions. Omeprazole was superior to famotidine with less gastrointestinal symptoms and\nrecurrent ulcers/erosions in patients using 24-week low-dose aspirin. The risk of erosive esophagitis, gastrointestinal bleeding, and\nthromboembolic events was similar between both groups.
Loading....